CAR-T Beyond Oncology Digital Summit

18/11/2020 - 18/11/2020

CAR-T therapy has taken the oncology world by storm. The 3rd CAR-T approval recently hit the headlines for Kite Pharma in mantle cell lymphoma.

Due to this clear clinical and commercial success, the oncology field has become saturated with companies with the hope to develop a cure… but are you aware of the new CAR-T movement beyond oncology?

The Digital CAR-T Beyond Oncology (November 18, 2020), the first and only meeting to highlight the clinical potential of next-generation CAR-T therapies in disease areas including autoimmunity, infection and inflammation, to guide your strategic portfolio growth.

Download the 1-day digital program here.

The Digital CAR-T Beyond Oncology presents an unrivalled opportunity to learn from these forward-thinking pioneers:

  • Philip Ashton-Rickardt, Senior Vice President, Immunology, AZTherapies
  • Blake Aftab, VP Preclinical & Translational Science, Atara Biotherapeutics
  • Arun Das, Senior Director, New Product Planning & Business Development, Cabaletta Bio
  • Michael Singer, Chief Scientific Officer, Cartesian Therapeutics
  • Renata Stripecke, Professor & Head of Laboratory, Hannover Medical School
  • Kumar Pappanaicken, Assistant Professor, MD Anderson Cancer Center
  • Thor Wagner, Assistant Professor of Pediatric Infectious Diseases, Seattle Children’s Hospital
  • Yong Chan Kim, Chief Executive Officer, TeraImmune, Inc
  • Scott Kitchen, Associate Professor of Medicine, Director, UCLA Humanized Mouse Core Laboratory, UCLA
  • Jonathan Epstein, Executive Vice Dean & CSO, William Wikoff Smith Professor of Medicine, University of Pennsylvania
  • Edward Rosloniec, Professor, University of Tennessee Health Science Center

The first-of-its-kind digital event will showcase CAR-T for Alzheimer’s disease, multiple sclerosis, HIV, herpesvirus, fibrosis, lupus and more!

Download the full program here.

Join this novel meeting to be brought up to speed on the clinical breakthroughs and proof-of-concept work in CAR-T beyond oncology, and take advantage of these learnings to inform your future growth strategies and indication expansion plans.

For more information visit or email us at